

Ipsogen strengthens its Management and Board of Directors

Marseille, 8th December 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company that develops, manufactures and markets tests for leukemia and breast cancer, today announces changes in its board and management team with the goal of providing increased management focus to execute its strategic plan.

Gilles Alberici, PhD, who joined the company's Board of Directors in 2007, has been elected non executive Chairman of the Board. As a seasoned biotechnology entrepreneur, Dr. Alberici brings 20 years of experience in the pharmaceutical industry. Founder of IMTIX (transplantation), President of IMTIX-SangStat, Gilles then founded OPi, a company dedicated to rare and severe diseases, in late 1999. The company was acquired by EUSA Pharma in March 2007. Gilles then set up Octalfa, a family-owned, independent investment company specializing in Life Sciences. In parallel and consistent with its independent approach and concern for public health, Octalfa established the Dominique Alberici-Octalfa Corporate Foundation to help cancer patients and disabled people, as well as supporting projects designed to improve their medical care.

Susan Hertzberg, MBA, currently President of Ipsogen Inc and VP Corporate Development is nominated CEO of Ipsogen US subsidiary. Prior to joining Ipsogen in 2007, Ms. Hertzberg served as General Manager, Global Accounts at Abbott Diagnostics. Before that, she spent much of her career at Quest Diagnostics and progressed through many management and leadership positions, including, Vice President, Purchasing and Materials Management, and Vice President, Marketing. Susan also has deep payor experience, both on the lab and managed care side, and was a Director at Oxford Health Plans. Susan holds an MBA from Columbia University, NY.

Pascale Boissel has been appointed Chief Financial Officer and member of Ipsogen Executive Committee to lead the financial department of Ipsogen. HEC graduate and chartered accountant Ms.Boissel started her career by joining one of the big four audit companies, Price Waterhouse Coopers. After 4 years in auditing and corporate finance consultancy, she joined the Danone Group as business controller where she was in charge of three divisions experiencing high growth. Vice President in the group Finance Team at Lafarge in her previous position, her professional background is mainly in corporate accounting and business control for large listed groups with a broad international exposure. She has a solid experience with international accountings and internal auditing standards.

"These changes reflect the ambition of Ipsogen and its executive management team in strongly supporting the business opportunities we see in the US for cancer molecular diagnostic testing

services and in Europe and Asia for cancer molecular diagnostic products. Gilles has been of tremendous help in the past two years as board member and I will increasingly rely on him to bring to reality the strategic vision of the company. Susan demonstrated an exceptional ability to execute our business plan in the US and I am confident that her new position will further help the company to reach the next level. We are also pleased to welcome Pascale, her strong experience in corporate finance at an international level will be of major importance in helping the team to drive our growth” said Vincent Fert, Chief Executive of Ipsogen.

“I am delighted to chair Ipsogen’s Board of Director since I strongly believe in the medical value of the assays and services developed by the company, which will bring new insights towards a more personalized approach to cancer patient care, both in hematology and breast cancer. This transition marks an important milestone for Ipsogen as we anticipate new products and services launches in the short and medium terms” added Gilles Alberici, Chairman of the Board.

About IPSOGEN

Ipsogen develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen’s goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of ‘companion diagnostic’ tests.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify develop and commercialize diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society. Ipsogen employed 70 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com

Contacts

IPSOGEN

Vincent Fert

CEO

Tel: + 33 (0)4 9129 3090

fert@ipsogen.com

NewCap

Financial communication & investor relations

Axelle Vuillermet & Pierre Laurent

Tel: + 33 (0)1 44 71 94 93 - ipsogen@newcap.fr

**Release of the 2009 sales:
17th of february 2010 (after market)**